Recent Updates
Recently added Catalysts
SKYE Negative Sentiment

Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SKYE

Key Takeaway: Skye Bioscience, Inc. is facing a class action lawsuit due to alleged violations of securities laws. The DJS Law Group is leading the lawsuit, asserting that Skye made false claims about the efficacy of its drug nimacimab. Affected shareholders are encouraged to participate in the case to pursue recovery for their losses. The class period for the lawsuit is from November 4, 2024, to October 3, 2025, with a deadline for participation set for January 16, 2026.
Price reaction · baseline $1.22 (2025-12-03 close) · hit after-hours · 4 other SKYE headline(s) in the window, move may be shared
day 0 close · peak
-0.8%

Market Sentiment Analysis

CONCERNS & RISKS

  • Skye Bioscience is facing a class action lawsuit for securities law violations.
  • The lawsuit claims that the company made false and misleading statements regarding the efficacy of its drug, nimacimab.
  • Shareholders are encouraged to reach out for potential recovery due to alleged misrepresentations.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
24.3%
average across 4 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
Nimacimab
Phase 2 · Obesity

Full Press Release Details

LOS ANGELES, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: November 4, 2024 to October 3, 2025
DEADLINE: January 16, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Skye’s nimacimab failed to demonstrate the efficacy it had previously claimed. Based on these facts, Skye’s public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
274 White Plains Road, Suite 1
Eastchester, NY 10709

Frequently Asked Questions

What is the class action lawsuit against Skye Bioscience about?

The lawsuit alleges Skye made false statements concerning its nimacimab's efficacy.

What is the class period for the Skye Bioscience lawsuit?

The class period is from November 4, 2024, to October 3, 2025.

What is the deadline for participation in the lawsuit?

The deadline to participate is January 16, 2026.

Do I need to be a lead plaintiff to recover losses?

Being a lead plaintiff is not necessary to recover losses in this case.

How can I enroll for updates regarding the case?

Shareholders can register to receive updates through portfolio monitoring software.

Last updated: Dec 4, 2025